ID27398A - Stabilisasi komposisi yang mengandung inhibitor ace dengan menggunakan magnesium oksida - Google Patents

Stabilisasi komposisi yang mengandung inhibitor ace dengan menggunakan magnesium oksida

Info

Publication number
ID27398A
ID27398A IDW20002515A ID20002515A ID27398A ID 27398 A ID27398 A ID 27398A ID W20002515 A IDW20002515 A ID W20002515A ID 20002515 A ID20002515 A ID 20002515A ID 27398 A ID27398 A ID 27398A
Authority
ID
Indonesia
Prior art keywords
stabilization
composition containing
magnesium oxide
ace inhibitors
containing ace
Prior art date
Application number
IDW20002515A
Other languages
English (en)
Indonesian (id)
Inventor
Jane Ellen Daniel
Michael Ray Harris
Gerard Clifford Hokason
Jay Weiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID27398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ID27398A publication Critical patent/ID27398A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW20002515A 1998-06-05 1999-05-10 Stabilisasi komposisi yang mengandung inhibitor ace dengan menggunakan magnesium oksida ID27398A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05

Publications (1)

Publication Number Publication Date
ID27398A true ID27398A (id) 2001-04-05

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002515A ID27398A (id) 1998-06-05 1999-05-10 Stabilisasi komposisi yang mengandung inhibitor ace dengan menggunakan magnesium oksida

Country Status (32)

Country Link
US (3) US6417196B1 (de)
EP (1) EP1083931B1 (de)
JP (1) JP3727848B2 (de)
KR (1) KR20010052557A (de)
CN (1) CN1144598C (de)
AR (1) AR019150A1 (de)
AT (1) ATE295184T1 (de)
AU (1) AU755616B2 (de)
BR (1) BR9910947A (de)
CA (1) CA2330581A1 (de)
CO (1) CO5011043A1 (de)
DE (1) DE69925269T2 (de)
ES (1) ES2242398T3 (de)
GT (1) GT199900079A (de)
HK (1) HK1038879B (de)
HN (1) HN1999000088A (de)
HU (1) HUP0102260A3 (de)
ID (1) ID27398A (de)
IL (1) IL139590A0 (de)
IS (1) IS2270B (de)
MY (1) MY119667A (de)
NO (1) NO20006148L (de)
NZ (1) NZ508544A (de)
PA (1) PA8475001A1 (de)
PE (1) PE20000543A1 (de)
PL (1) PL344586A1 (de)
SV (1) SV1999000072A (de)
TR (1) TR200003600T2 (de)
TW (1) TW565455B (de)
UY (1) UY25546A1 (de)
WO (1) WO1999062560A1 (de)
ZA (1) ZA200006537B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330581A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
JP4902928B2 (ja) * 2000-05-24 2012-03-21 大塚製薬株式会社 製剤の安定化方法
US20050118259A1 (en) * 2002-01-15 2005-06-02 Renir Eyjolfsson Formulations of quinapril and related ace nhibitors
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
USRE45404E1 (en) 2003-03-27 2015-03-03 Shin Nippon Biomedical Laboratories, Ltd. Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
DK1635792T3 (da) * 2003-06-26 2009-06-15 Teva Pharma Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US8779175B2 (en) * 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (de) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. Pharmazeutische Zusammensetzung enthaltend Perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
RU2008145115A (ru) * 2006-04-19 2010-05-27 Тева Фармасьютикл Индастриес Лтд. (Il) Стабильные фармацевтические композиции производственных соединений 2-аза-бицикло[3.3.0]-октан-3-карбоновой кислоты
EP2034966A1 (de) * 2006-06-30 2009-03-18 Alphapharm Pty Ltd. Stabilisierte zusammensetzung mit ace-hemmern
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) * 1967-05-16 Method of preparing magnesia
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
CA2330581A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
ATE295184T1 (de) 2005-05-15
JP2002516881A (ja) 2002-06-11
US20020161020A1 (en) 2002-10-31
DE69925269D1 (de) 2005-06-16
SV1999000072A (es) 2000-05-04
PA8475001A1 (es) 2000-09-29
EP1083931A1 (de) 2001-03-21
US6417196B1 (en) 2002-07-09
IS2270B (is) 2007-07-15
HN1999000088A (es) 2000-02-10
NO20006148D0 (no) 2000-12-04
UY25546A1 (es) 1999-09-27
AU755616B2 (en) 2002-12-19
TR200003600T2 (tr) 2001-04-20
CN1144598C (zh) 2004-04-07
AU3979399A (en) 1999-12-20
KR20010052557A (ko) 2001-06-25
WO1999062560A1 (en) 1999-12-09
NO20006148L (no) 2000-12-04
TW565455B (en) 2003-12-11
HK1038879A1 (en) 2002-04-04
CO5011043A1 (es) 2001-02-28
IS5712A (is) 2000-11-10
JP3727848B2 (ja) 2005-12-21
HK1038879B (zh) 2004-10-08
MY119667A (en) 2005-06-30
US20060106057A1 (en) 2006-05-18
HUP0102260A2 (hu) 2002-03-28
ZA200006537B (en) 2001-11-12
US7015232B2 (en) 2006-03-21
PL344586A1 (en) 2001-11-05
DE69925269T2 (de) 2006-02-23
AR019150A1 (es) 2001-12-26
PE20000543A1 (es) 2000-08-10
NZ508544A (en) 2002-10-25
ES2242398T3 (es) 2005-11-01
HUP0102260A3 (en) 2002-12-28
IL139590A0 (en) 2002-02-10
CN1304322A (zh) 2001-07-18
GT199900079A (es) 2000-11-25
CA2330581A1 (en) 1999-12-09
BR9910947A (pt) 2001-03-06
EP1083931B1 (de) 2005-05-11

Similar Documents

Publication Publication Date Title
HUP0102260A3 (en) Stabilization of compositions containing ace inhibitors using magnesium oxide
AU2524902A (en) Use of MoO<sub>3</sub> as corrosion inhibitor, and coating composition containing such an inhibitor
IS5739A (is) Efnasambönd óstöðugra DP IV-lata
HUP0302991A3 (en) Isoxazoles and their use as inhibitors of erk and pharmaceutical compositions containing the compounds
AU2002357137A8 (en) (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
IL137540A0 (en) Inhibitors of phospholipase a2
EE05430B1 (et) Imidasolo-5-l-2-anilino-primidiinid raku proliferatsiooni inhibitsiooni agensitena
FI941766L (fi) sPLA2:n 1H-indoli-3-etikkahappohydratsidi-inhibiittoreita
HUS1500068I1 (hu) Dezacetiláz inhibitor hatású hidroxamát származékok és ezeket tartalmazó gyógyszerkészítmények
HUP0400475A3 (en) Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof
AP1967A (en) Thiazolidinone compounds as inhibitors of Hyak3
PL350228A1 (en) Dimeric compounds and as inhibitors of neuraminidase
IS6254A (is) Lyfjasamsetningar sem innihalda HMG afoxunarensímlata
IL140244A0 (en) Heterocyclic compounds as inhibitors of rotamase enzymes
EE200300248A (et) GABA agonistide ja sorbitooldehüdrogenaasi inhibiitorite kombinatsioon
EE200300201A (et) Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos
PL369312A1 (en) Novel compounds and compositions as cathepsin inhibitors
IL159125A0 (en) Novel compounds and compositions as cathepsin inhibitors
IL144348A0 (en) Alkynyl containing hydroxamic acid compounds as tace inhibitors
IL138601A0 (en) Pyrrolidines as inhibitors of neuraminidases
ATE287416T1 (de) Thrombin inhibitoren
GB2337518B (en) Dissolution inhibitor of chemically amplified photoresist and chemically amplified photoresist composition containing the same
AU2002211853A1 (en) Use of mek1 inhibitors as protective agents against damage due to ischemia
ATE271047T1 (de) Type 1 inhibitorkristalle als inhibitoren des natrium-protonen austauschs
IL144321A0 (en) ACETYLENIC β-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID AS TACE INHIBITORS